kabutan

Oncolys BioPharma Inc.(4588) Summary

4588
TSE Growth
Oncolys BioPharma Inc.
2,831
JPY
-46
(-1.60%)
Apr 30, 9:01 am JST
17.37
USD
Apr 29, 8:02 pm EDT
Result
PTS
outside of trading hours
2,768
Apr 30, 9:02 am JST
Summary Chart Historical News Financial Result
PER
PBR
20.8
Yield
ー%
Margin Trading Ratio
1,106.35
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
2,860 JPY 17.85 USD
Previous Close Apr 28
2,877 JPY 18.07 USD
High Apr 30, 9:00 am
2,921 JPY 18.23 USD
Low Apr 30, 9:01 am
2,830 JPY 17.24 USD
Volume
43,000
Trading Value
0.12B JPY 1.63M USD
VWAP
2869.52 JPY 17.66 USD
Minimum Trading Value
283,100 JPY 1,737 USD
Market Cap
0.08T JPY 0.51B USD
Number of Trades
137
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
3,953
1-Year High Dec 30, 2025
44,420
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 100 6,029,300 60293.00
Apr 17, 2026 2,200 6,073,000 2760.45
Apr 10, 2026 3,000 6,197,300 2065.77
Apr 3, 2026 0 6,207,000
Mar 27, 2026 2,800 6,284,000 2244.29
Company Profile
Oncolys BioPharma Inc. is a drug discovery venture focusing on rare cancers and severe infectious diseases, utilizing proprietary virus technology.
Sector
Pharmaceuticals
Oncolys BioPharma Inc. promotes the development of cancer virus therapy and severe infectious disease treatments using its proprietary virus genetic modification technology. Its main pipeline includes Telomelysin, which specifically proliferates in cancer cells, and OBP-702, a next-generation Telomelysin with even more potent anti-cancer activity. Additionally, OBP-601, which has been developed as an HIV infection treatment, is now being repurposed as a treatment for neurodegenerative diseases. The company is also developing OBP-2011 as a viral infection treatment. Oncolys BioPharma Inc. is also working on TelomeScan, a cancer diagnostic agent for ultra-early detection or prognosis testing of cancer. The company employs a fabless management strategy to optimize development efficiency and expenses.